3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Head & Neck
2
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Trastuzumab
87
Cyclophosphamide
67
Capecitabine
67
Paclitaxel
64
Docetaxel
58
Fulvestrant
52
Letrozole
50
Carboplatin
42
pembrolizumab
41
Lapatinib
38
Doxorubicin
36
Anastrozole
32
Vinorelbine
31
Bevacizumab
31
exemestane
28
Tamoxifen
25
Gemcitabine
25
Albumin-Bound Paclitaxel
25
Radiotherapy
21
Taxes
19
atezolizumab
18
pertuzumab
17
Everolimus
17
130-nm albumin-bound paclitaxel
17
Epirubicin
16
palbociclib
15
Magnetic Resonance Spectroscopy
15
eribulin
14
Ado-Trastuzumab Emtansine
14
Goserelin
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
utomilumab
×
Breast
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts